Evidence map›Paper›PMID 37086297›Full record

ArticleMolecular biology reports2023

Effects of quercetin on hepatic fibroblast growth factor-21 (FGF-21) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) levels in rats fed with high fructose.

Kardelen Kocaman Kalkan, Serkan Şen, Belkıs Narlı, Cemile Merve Seymen, Canan Yılmaz

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kardelen Kocaman KalkanDepartment of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey. kocamankardelenn@gmail.com.ORCID http://orcid.org/0000-0002-5749-5687
Serkan ŞenAtaturk Vocational School of Health Services, Afyonkarahisar University of Health Sciences, Afyon, Turkey.ORCID http://orcid.org/0000-0002-2884-4753
Belkıs NarlıDepartment of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey.ORCID http://orcid.org/0000-0002-0629-034X
Cemile Merve SeymenDepartment of Histology and Embryology, Gazi University Faculty of Medicine, Ankara, Turkey.ORCID http://orcid.org/0000-0002-8945-3801
Canan YılmazDepartment of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey.ORCID http://orcid.org/0000-0002-6799-6522
Gazi University · TRSağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAvailable studies show that quercetin reduces Metabolic Syndrome (MetS) and its complications, increases insulin sensitivity and improves glucose levels. It has been reported that the increase in hepatic gene expressions of fibroblast growth factor-21 (FGF-21), an important metabolic regulator of insulin sensitivity, glucose and energy homeostasis, and peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), which plays a central role in the regulation of cellular energy metabolism, eliminate the negative effects of fructose in fructose-fed rats. The main purpose of our study is to examine the effects of quercetin on hepatic FGF-21 and PGC-1α expressions and levels, as well as its protective and therapeutic role on MetS components in rats fed with fructose. METHODS AND

resultsIn our study, 24 Sprague Dawley male rats were divided into 4 groups: control, fructose, quercetin, fructose+quercetin (n = 6). During the 10-week experiment, quercetin was administered at a daily dose of 15 mg/kg body weight and fructose at a rate of 20%. Blood pressure and weights of all groups were measured and recorded. At the end of week 10, blood and liver tissue samples were taken. Serum insulin, glucose and triglyceride, total, HDL and VLDL cholesterol levels were determined from the samples. Insulin resistance was calculated using the HOMA-IR formula. Hepatic PGC-1α and FGF-21 protein levels and their mRNA expressions were determined. Criteria for metabolic syndrome were successfully established with fructose. It was observed that the administration of quercetin alone and in combination with fructose exerted positive effects and improved MetS criteria. It was determined that the administration of quercetin increased hepatic FGF-21 and PGC-1α protein levels and Messenger RNA (mRNA) expressions of them, which were decreased by fructose application.

conclusionsThe results of our study showed that 10-week administration of quercetin at 15 mg/kg exerted beneficial effects on lipid and carbohydrate metabolism in the fructose-mediated MetS model; therefore, quercetin may have great potential in the prevention and treatment of metabolic disorders.

Indexed as

Insulin ResistanceMetabolic SyndromeAnimalsFibroblast Growth FactorsFructoseGlucoseLiverMalePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaQuercetinRatsRats, Sprague-DawleyRNA, Messengerfibroblast growth factor 21Fibroblast Growth FactorsFructoseGlucosePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaQuercetinRNA, MessengerFGF-21FructoseLiverPGC-1αQuercetin

Identifiers

PMID37086297
OpenAlexW4366742754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.